CORONA vs FREDUN: Stock Comparison
CORONA REMEDIES shows a higher dividend yield and a higher net margin, while FREDUN PHARMACEUTICALS L shows a lower P/E. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
CORONA leads 4; FREDUN leads 2 of 9
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Price
| Metric | CORONA | FREDUN |
|---|---|---|
| Live Price | ₹2,152.5 | ₹1,280 |
| Day Change | 0.42% | 4.78% |
| Volume | 6,287 | 97,984 |
| 52-Week High | ₹2,292.4 | ₹1,590 |
| 52-Week Low | ₹1,336.6 | ₹1,195.2 |
| Distance from 52W High | -6.1% | -19.5% |
Valuation
| Metric | CORONA | FREDUN |
|---|---|---|
| Market Cap | ₹13,087 Cr | ₹0 Cr |
| P/E Ratio | 66.97x | 0x |
| P/B Ratio | 17.84x | 0x |
| EPS | ₹9.83 | ₹7.94 |
| Book Value | ₹122.12 | ₹168.16 |
| Dividend Yield | 0.46% | 0.11% |
Growth
| Metric | CORONA | FREDUN |
|---|---|---|
| Revenue Growth (TTM YoY) | 0% | 0% |
| EPS Growth (TTM YoY) | 0% | 0% |
| Qtr Sales Growth | 0% | 0% |
| Qtr Profit Growth | -0.02% | -0.27% |
Profitability & Leverage
| Metric | CORONA | FREDUN |
|---|---|---|
| ROE | 24.28% | — |
| ROCE | 20.94% | — |
| Net Margin | 13.19% | 0% |
| Operating Margin | 15.89% | — |
| Debt to Equity | 0.19x | — |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | CORONA | FREDUN |
|---|---|---|
| Promoter Holding | 69% | 44.57%▲ 0.4 pp |
| FII Holding | 3.63%▲ 1.38 pp | 1.06% |
| DII Holding | 12.9%▲ 5.88 pp | 2.94%▲ 0.11 pp |
| Public Holding | 14.48%▼ 7.26 pp | 51.43%▼ 0.51 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: CORONA REMEDIES and FREDUN PHARMACEUTICALS L.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.